Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a cure for multiple myeloma within a decade.

Blood cancer journal·2026
Same author

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025.

European journal of haematology·2026
Same author

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Blood cancer journal·2025
Same author

Precision medicine for multiple myeloma: The case for translocation (11;14).

Cancer treatment reviews·2024
Same author

A roadmap towards improving outcomes in multiple myeloma.

Blood cancer journal·2024
Same author

Potential future direction of measurable residual disease evaluation in multiple myeloma.

Blood·2023

Related Experiment Video

Updated: Jun 27, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Induction therapy in multiple myeloma.

Jean-Luc Harousseau1

  • 1Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France. jean-luc.harousseau@univ-nantes.fr

Hematology. American Society of Hematology. Education Program
|December 17, 2008
PubMed
Summary

Novel agents significantly improve complete remission (CR) rates in multiple myeloma induction therapy, especially when combined with high-dose therapy and autologous stem-cell transplantation (ASCT). These advancements enhance outcomes for both ASCT-eligible and ineligible patients.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Experiment Videos

Last Updated: Jun 27, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Complete remission (CR) is the primary goal of induction treatment in hematologic malignancies.
  • High-dose therapy with autologous stem-cell transplantation (ASCT) is crucial for achieving CR in multiple myeloma.
  • Achieving CR or very good partial remission (VGPR) correlates with improved progression-free and overall survival in ASCT for multiple myeloma.

Purpose of the Study:

  • To evaluate the impact of novel agents on induction treatment for multiple myeloma.
  • To compare the efficacy of novel agent combinations with traditional therapies.
  • To assess outcomes in both ASCT-eligible and ineligible multiple myeloma patients.

Main Methods:

  • Analysis of induction treatment regimens including dexamethasone, vincristine-adriamycin (VAD), and high-dose melphalan.
  • Evaluation of novel agents like thalidomide, bortezomib, and lenalidomide in combination therapies.
  • Assessment of CR/VGPR rates in patients undergoing ASCT and in elderly, non-ASCT candidates.

Main Results:

  • Traditional high-dose therapy achieves 20-40% CR and 40-55% CR/VGPR.
  • Novel agent combinations (dexamethasone with thalidomide, bortezomib, or lenalidomide) increase CR/VGPR rates.
  • Triple combinations show post-ASCT CR/VGPR rates of 60-75%.
  • Elderly patients not eligible for ASCT achieve comparable CR/VGPR rates with melphalan-prednisone plus a novel agent.
  • Prolonged lenalidomide plus dexamethasone treatment yields up to 70% CR/VGPR.

Conclusions:

  • Novel agents are transforming multiple myeloma induction therapy, significantly improving remission rates.
  • Combination therapies including novel agents offer superior efficacy compared to older regimens.
  • Effective treatment options are now available for both ASCT-eligible and ineligible multiple myeloma patients, including the elderly.